News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
672,368 Results
Type
Article (60383)
Company Profile (202)
Press Release (611783)
Multimedia
Podcasts (99)
Webinars (11)
Section
Business (181989)
Career Advice (3082)
Deals (32968)
Drug Delivery (128)
Drug Development (83587)
Employer Resources (173)
FDA (16899)
Job Trends (14986)
News (325720)
Policy (35276)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Biotech Bay Standard (12)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (4)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2892)
Academic (2)
Accelerated approval (6)
Adcomms (28)
Allergies (86)
Alliances (47245)
ALS (95)
Alzheimer's disease (1456)
Antibody-drug conjugate (ADC) (144)
Approvals (16870)
Artificial intelligence (271)
Autoimmune disease (25)
Automation (9)
Bankruptcy (308)
Best Places to Work (11824)
BIOSECURE Act (20)
Biosimilars (116)
Biotechnology (149)
Bladder cancer (68)
Brain cancer (31)
Breast cancer (283)
Cancer (2217)
Cardiovascular disease (185)
Career advice (2595)
Career pathing (33)
CAR-T (155)
Cell therapy (421)
Cervical cancer (21)
Clinical research (67496)
Collaboration (827)
Compensation (444)
Complete response letters (29)
COVID-19 (2809)
CRISPR (43)
C-suite (220)
Cystic fibrosis (104)
Data (2065)
Decentralized trials (2)
Denatured (25)
Depression (51)
Diabetes (282)
Diagnostics (6368)
Digital health (16)
Diversity (9)
Diversity, equity & inclusion (42)
Drug discovery (134)
Drug pricing (124)
Drug shortages (33)
Duchenne muscular dystrophy (96)
Earnings (72162)
Editorial (43)
Employer branding (22)
Employer resources (152)
Events (101277)
Executive appointments (658)
FDA (18136)
Featured Employer (44)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (717)
Gene editing (105)
Generative AI (29)
Gene therapy (317)
GLP-1 (822)
Government (4984)
Grass and pollen (4)
Guidances (46)
Healthcare (19395)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (132)
Indications (28)
Infectious disease (2961)
Inflammatory bowel disease (138)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (94)
Interviews (555)
IPO (16109)
IRA (51)
Job creations (3586)
Job search strategy (2152)
Kidney cancer (10)
Labor market (29)
Layoffs (503)
Leadership (21)
Legal (7865)
Liver cancer (78)
Lung cancer (319)
Lymphoma (144)
Machine learning (5)
Management (61)
Manufacturing (302)
MASH (68)
Medical device (13063)
Medtech (13068)
Mergers & acquisitions (17395)
Metabolic disorders (745)
Multiple sclerosis (80)
NASH (23)
Neurodegenerative disease (102)
Neuropsychiatric disorders (29)
Neuroscience (2008)
NextGen: Class of 2025 (6819)
Non-profit (4875)
Northern California (2431)
Now hiring (24)
Obesity (407)
Opinion (269)
Ovarian cancer (75)
Pain (89)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (20)
Patents (230)
Patient recruitment (98)
Peanut (49)
People (51440)
Pharmaceutical (44)
Pharmacy benefit managers (21)
Phase I (20778)
Phase II (29450)
Phase III (22420)
Pipeline (1130)
Policy (155)
Postmarket research (3040)
Preclinical (8929)
Press Release (62)
Prostate cancer (100)
Psychedelics (37)
Radiopharmaceuticals (265)
Rare diseases (408)
Real estate (5503)
Recruiting (71)
Regulatory (24626)
Reports (35)
Research institute (2580)
Resumes & cover letters (518)
Rett syndrome (4)
RNA editing (4)
RSV (48)
Schizophrenia (75)
Series A (123)
Series B (78)
Service/supplier (8)
Sickle cell disease (58)
Southern California (2108)
Special edition (18)
Spinal muscular atrophy (161)
Sponsored (30)
Startups (3424)
State (2)
Stomach cancer (15)
Supply chain (69)
Tariffs (30)
The Weekly (72)
United States (21372)
Vaccines (748)
Venture capitalists (39)
Weight loss (293)
Women's health (35)
Worklife (19)
Date
Today (94)
Last 7 days (446)
Last 30 days (2263)
Last 365 days (32755)
2025 (9314)
2024 (35239)
2023 (40402)
2022 (51255)
2021 (55740)
2020 (54426)
2019 (48119)
2018 (36492)
2017 (32575)
2016 (31684)
2015 (36187)
2014 (28509)
2013 (24161)
2012 (25880)
2011 (26484)
2010 (24464)
Location
Africa (971)
Alabama (58)
Alaska (6)
Arizona (186)
Arkansas (13)
Asia (41301)
Australia (6988)
California (5535)
Canada (1905)
China (513)
Colorado (247)
Connecticut (263)
Delaware (141)
Europe (91939)
Florida (849)
Georgia (198)
Idaho (54)
Illinois (523)
India (28)
Indiana (271)
Iowa (7)
Japan (154)
Kansas (100)
Kentucky (24)
Louisiana (7)
Maine (60)
Maryland (877)
Massachusetts (4207)
Michigan (179)
Minnesota (362)
Mississippi (2)
Missouri (75)
Montana (25)
Nebraska (25)
Nevada (52)
New Hampshire (62)
New Jersey (1632)
New Mexico (30)
New York (1630)
North Carolina (952)
North Dakota (6)
Northern California (2431)
Ohio (186)
Oklahoma (14)
Oregon (34)
Pennsylvania (1220)
Puerto Rico (9)
Rhode Island (29)
South America (1268)
South Carolina (19)
South Dakota (1)
Southern California (2108)
Tennessee (98)
Texas (815)
Utah (161)
Virginia (142)
Washington D.C. (60)
Washington State (511)
West Virginia (3)
Wisconsin (52)
672,368 Results for "national institute on drug abuse".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.
March 14, 2024
·
3 min read
Bio NC
Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody
Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).
October 18, 2023
·
4 min read
Pharm Country
Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH’s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder
Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.
August 28, 2023
·
4 min read
Biotech Bay
MAPS PBC Announces National Institute on Drug Abuse to Share Data for New Drug Application for MDMA-Assisted Therapy for Treatment of PTSD
MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).
June 21, 2023
·
5 min read
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Biotech Beach
Camino Pharma receives $1.97M Small Business Innovation Research (SBIR) Grant from the National Institute of Alcohol Abuse and Alcoholism
Camino Pharma, LLC announced that its co-founder and CSO, Reto Gadient, Ph.D., has been awarded a two-year, $1.97M grant by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number U43AA031388 and is the Principal Investigator on the grant.
December 7, 2023
·
4 min read
Press Releases
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
April 21, 2025
·
4 min read
Press Releases
Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib
April 14, 2025
·
5 min read
Genetown
Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders
Delix Therapeutics today announced it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support the advancement of DLX-007.
December 13, 2023
·
5 min read
Business
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
April 10, 2023
·
6 min read
1 of 67,237
Next